Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) saw an upside of 9.20% to close Tuesday at $17.56 after adding $1.48 on the day. The 5-day average trading volume is 681,920 shares of the company’s common stock. It has gained $17.64 in the past week. An average of 733,845 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,017,138.
ICPT’s 1-month performance is 18.81% or $2.91 on its low of $14.21 reached on 10/06/21. The company’s shares have touched a 52-week low of $11.60 and high of $40.41, with the stock’s rally to the 52-week high happening on 01/27/21. YTD, ICPT has lost -28.91% or -$7.14. However, the current price is down -56.55%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Jan 05, 281 days have gone by since the last insider trading activity for Intercept Pharmaceuticals Inc. (ICPT). Kapadia Sandip (CFO and Treasurer) most recently sold 2,193 shares at $24.47 per share on Jan 05. This transaction cost the insider $53,663. CFO and Treasurer, Kapadia Sandip, sold 1,763 shares at a price of $32.78 on Dec 15.
Intercept Pharmaceuticals Inc. (ICPT) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.ICPT stock has a beta of 1.37. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.68.
Intercept Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 3.40, with the current ratio over the same period at 3.40 meaning that ICPT stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 98.80%. The trailing 12-month EBITDA margin is -66.31% while for the period ending June 29; Intercept Pharmaceuticals Inc.’s operating margin was -36.40%. The firm’s gross profit as reported stood at $307.37 million against revenue of $312.69 million.
For the quarterly period ending June 29 this year, Intercept Pharmaceuticals Inc.’s cash and short-term investments amounted to $268.8 million against total debt of $587.27 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ICPT to announce -$1.22 per share in earnings in its latest quarter, but it posted -$0.33, representing a 73.00% surprise. EBITDA for the quarter stood at more than $10.42 million. ICPT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 726.42 million, with total debt at $587.27 million. Shareholders hold equity totaling $33.2 million
Let’s look briefly at Intercept Pharmaceuticals Inc. (ICPT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 74.40% to suggest the stock is trending Overbought, with historical volatility in this time period at 60.78%.
The stock’s 5-day moving average is $15.55, reflecting a +21.78% or $3.14 change from its current price. ICPT is currently trading +15.91% above its 20-day SMA, +1.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +1.21% and -34.45% respectively.
Stochastic %K and %D was 68.31% and 43.83% and the average true range (ATR) pointed at 0.87. The RSI (14) points at 67.38%, while the 14-day stochastic is at 97.67% with the period’s ATR at 0.83. The stock’s 9-day MACD Oscillator is pointing at 0.97 and 0.72 on the 14-day charts.
In the most recent analyst report for Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Goldman downgraded it to a Sell rating. They previously had a Neutral rating on the stock. Analysts offering their rating for ICPT stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate ICPT as a “sell,”, while 12 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 2 rates the stock as overweight while 2 have offered a “buy” rating.
What is ICPT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $82.00, with their median price target at $23.00. Looking at these predictions, the average price target given by analysts is for Intercept Pharmaceuticals Inc. (ICPT) stock is $29.12.